Advertisement
Advertisement
May 26, 2026
Microbot’s Liberty Endovascular Robotic System Receives Marketing Clearance in Israel
KEY TAKEAWAYS
- Microbot Medical’s Liberty endovascular robotic system receives marketing clearance in Israel for peripheral endovascular procedures.
- The single-use, remotely operated system is designed for precise vascular navigation while reducing radiation exposure.
- Microbot recently received clearance and launched Liberty in the United States and is pursuing CE Mark in Europe.
May 26, 2026—Microbot Medical Inc. announced that its Liberty endovascular robotic system has achieved regulatory marketing clearance from the Israel Ministry of Health’s AMAR Division.
According to the company, the clearance allows Microbot to market and commercialize the Liberty system in Israel and enables the company to obtain a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions.
Microbot stated that Liberty is a single-use, remotely operated robotic system for peripheral endovascular procedures. It is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.
The company advised that it continues to pursue CE Mark certification and is working toward completion by the end of 2026.
In September 2025, Microbot announced FDA 510(k) clearance for the single-use, remotely operated Liberty endovascular robotic system for peripheral endovascular procedures. In April 2026, the company announced it had executed a limited market release, followed by a full market release.
Advertisement
Advertisement
